PLOD1 and central precocious puberty: Six-month 45-mg subcutaneous leuprolide acetate suppressed peak LH and gonadal sex steroids to prepubertal levels in >85% of the children at all study assessments and, therefore, may be considered effective for the treatment of children with CPP.